NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Burning Rock Biotech Limited (BNR) Stock Analysis

Burning Rock Biotech Limited (BNR) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

BNR

$11.99

+$1.21 (+11.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNR with… →

BNR Key Statistics

As of Sep 4, 2026
Trading
Open
$10.16
Previous Close
$10.78
Day's Range
10.16–12.05
52-Week Range
6.79–41.72
Volume
97.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.39
Valuation
Market Cap
$126.45M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.94
Financials (FY)
Revenue (FY)
$539.57M+4.60%
Net Income (FY)
−$55.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
−11.53%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.81M
1-Year Return
+41.89%
Dividend and dates
Avg Volume
17.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BNR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−40.50%
2025+198.52%
2024−27.42%
2023−58.67%
2022−76.39%
2021−58.74%
2020 (partial year)−6.21%

As of September 4, 2026.

BNR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$539.57M−$55.35M−10.3%
2024$515.82M−$346.63M−67.2%
2023$537.44M−$653.69M−121.6%
2022$563.24M−$971.23M−172.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$539.57M$402.91M−$54.85M−$55.35M−10.3%
2024$515.82M$362.40M−$322.43M−$346.63M−67.2%
2023$537.44M$363.23M−$669.32M−$653.69M−121.6%
2022$563.24M$380.04M−$980.41M−$971.23M−172.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BNR Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricBNRDiagnostics & Research medianvs median
P/S ratio0.254.990.0x the median
Profit margin−11.53%0.00%11.5 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Burning Rock Biotech Limited (BNR) carries a market capitalisation of $126.45M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 667 employees.

BNR last closed at $11.99 on September 4, 2026. That is +$1.21 (+11.22%) against the previous close. Over the past 52 weeks the price has ranged from $6.79 to $41.72. The latest close sits 76.58% above that 52-week low.

Financial Health

In fiscal 2025, Burning Rock Biotech Limited reported revenue of $539.57M. That is +4.60% against the prior fiscal year, when revenue was $515.82M. The same year closed with a net loss of $55.35M. Profit margin runs at −11.53%. That is 11.5 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −0.94.

Across the 4 fiscal years on file, revenue moves from $563.24M in 2022 to $539.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.25. On price-to-sales that is 0 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The reported beta is 1.39. Daily returns over the trailing 6 years annualize to a volatility of 96.7%. Over the trailing twelve months the price has returned +41.89%. Across 5 years the annualized return works out at −43.33%.

Growth & Income

The record shows no dividend for BNR.

2026 is still running; the price is −40.50% year to date. Across the complete calendar years on file, 2025 returned +198.52% and 2022 returned −76.39%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Burning Rock Biotech Limited (BNR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Burning Rock Biotech Limited BNR $126.45M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Burning Rock Biotech Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Burning Rock Biotech Limited

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Visit website →